comprehensive -WSS

comprehensive

author：fashion 2025-09-27 16:23:47 - browse：642

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The health care issue Democrats can’t solve: hospital reform

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

All of Us, NIH's precision medicine initiative, gets a big boost

Lung cancer screening guidelines updated for cigarette smokers

Amylyx ALS drug fails large clinical trial

Gene therapy’s promise and the high cost of hope

focus

comprehensive

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

Explaining an after

Dobbs anniversary: the lost opportunity of abortion as health care

Amylyx ALS drug fails large clinical trial

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Infant mortality in U.S. rose last year for first time in decades: CDC

BioMarin wins approval for gene therapy to treat hemophilia A

The Readout: Amylyx, Alumis, and Lundbeck drug updates

23andMe had bad news about my health. I wish a person had delivered it

A deep dive into Applied Therapeutics’ data, and questions on Cassava

entertainment

Air quality improving but still lags in Black, Hispanic communities

Infant mortality in U.S. rose last year for first time in decades: CDC

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Live blog: Hearing on CRISPR

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Key Senate panel to consider PBM, drug pricing reform package

entertainment

hotspot

focus

focus